Improvement of Compliance for High Doses of EPA Amongst Patients With Colorectal Cancer

Fish Oil Supplementation in Cancer Patients - Capsules or in Nutritional Supplements. A Controlled Trial of Compliance.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03751384

Enrollment

Registered

2018-11-23

Start date

2015-05-18

Completion date

2018-11-10

Last updated

2018-11-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Compliance, Abdominal Cancer

Brief summary

Several studies indicate beneficial effects of eicosapentanoic acid (EPA) on cancer cachexia. However, compliance is generally low. This case control study is conducted in order to investigate if compliance depends upon the physical properties of the supplement (capsules vs. drinks). In order to further investigate how compliance can be improved, a possible correlation between sideeffects and rate of increased polyunsaturated fatty acid concentration in blood is also tested

Detailed description

Patients with abdominal cancer in active chemotherapeutic were allocated to either EPA in an oral nutritional drink (commercial) or capsules with fish oil. The dose of EPA was the same in both groups, and diets were adjusted as iso-caloric. Compliance to the fish oil treatment was the primary outcome. Blood concentrations of EPA secondary.

Interventions

DIETARY_SUPPLEMENTMöllers Omega-3 Ekstra Sterk

DIETARY_SUPPLEMENTNutrifriend Cachexia

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

SINGLE (Outcomes Assessor)

Masking description

pseudo-anonymized

Intervention model description

Allocation, not randomized

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients receiving chemotherapy on Rigshospitalet due to colorectal cancer * Not terminally ill * Subjects must be18 years of age (or older)

Exclusion criteria

* Subjects who do not read/speak/understand Danish * Familial hypercholesterolemia * Predialytic patients (GFR \< 15 ml/min/1,73 m2 or creatinine ≥ 500 mmol/L) * Use of blood thinners * Bleeder's disease

Design outcomes

Primary

Measure	Time frame	Description
Compliance	4 weeks	Number of Capsules and bottles counted

Secondary

Measure	Time frame	Description
Erythrocyte concentration of EPA	4 weeks	Concentration measured on isolated erythrocytes

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026